TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Being Patient interview with University of British Columbia researcher Cheryl Wellington examines how cholesterol in the bloodstream and brain may affect neurological health. Wellington cited research linking high LDL in midlife with an estimated 7% to 9% higher risk of Alzheimer’s disease and related dementias, but the interview does not establish that lowering LDL prevents dementia.
In a Being Patient interview, University of British Columbia researcher Cheryl Wellington discussed how cholesterol may affect brain and blood-vessel health, and why high LDL in midlife has been linked to dementia risk. Wellington cited an estimated 7% to 9% increase in Alzheimer’s disease and related dementia risk associated with high midlife LDL, while emphasizing that cholesterol in the bloodstream and cholesterol in the brain are distinct.
Wellington, a professor and vice chair of research in the university’s Department of Pathology and Laboratory Medicine, studies cholesterol and proteins that transport it, including ApoE. She told Being Patient that the blood-brain barrier limits direct exchange between blood and brain, so cholesterol circulating in the blood does not simply pass into the brain. Still, she said cholesterol can affect neurological health through processes within brain tissue and through the blood vessels supplying it.
In the interview, Wellington connected elevated LDL—often called “bad” cholesterol—to atherosclerotic plaque in blood vessels and reduced blood flow. She said this vascular disease commonly occurs alongside Alzheimer’s pathology. She also described a separate process involving amyloid-beta, a protein produced in the brain that is normally cleared through drainage pathways, including during sleep. The interview material says cholesterol may interfere with that clearance, but does not provide a study citation or detailed evidence for the claim.
Wellington also discussed the possibility that cholesterol accumulation in the brain’s immune cells contributes to inflammation, particularly among people with the ApoE4 gene variant. She suggested that lowering LDL earlier in life could be more beneficial than beginning treatment after symptoms appear. These points reflect the researcher’s discussion; the source does not report a new clinical trial or establish that cholesterol-lowering treatment prevents Alzheimer’s disease.
Midlife LDL and Dementia Risk
The interview draws attention to a potential connection between cardiovascular health and brain health. LDL is commonly measured and managed because of its role in heart and blood-vessel disease; Wellington’s account says midlife levels may also be relevant to later dementia risk. Damage to vessels supplying the brain could affect its function, while processes inside the brain may influence how proteins associated with Alzheimer’s are handled.
For readers, the distinction is between an association and a proven prevention strategy. Wellington’s cited 7% to 9% estimate concerns increased risk linked to high LDL, not an individual’s certainty of developing dementia. The interview also does not show that lowering cholesterol by a specific amount will reduce a person’s Alzheimer’s risk by a corresponding percentage. Decisions about cholesterol testing or treatment should be made with a qualified health professional, based on a person’s overall health and clinical evidence.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Philips Sonicare ProtectiveClean 5300 Rechargeable Electric Toothbrush with 3 Brush Heads, Black
As an affiliate, we earn on qualifying purchases.
Two Cholesterol Systems in the Brain
Cholesterol is needed by the body, and the brain has its own cholesterol processes. As Wellington explained, the blood-brain barrier separates much of the brain’s interior from substances circulating in the blood. That means blood cholesterol and brain cholesterol should not be treated as one shared pool, even though both may be relevant to neurological health.
The interview also distinguishes atherosclerotic plaque, which forms in blood vessels, from amyloid plaques associated with Alzheimer’s disease. Wellington said the two types of pathology can occur together, but they are not the same thing. Being Patient disclosed that NewAmsterdam Pharma supported production of the Live Talk and said the sponsor had no role in selecting guests, shaping questions or reviewing the content before publication.
“Especially in people’s midlife years, high LDL increases the risk of Alzheimer’s disease and related dementias, estimated by about 7 to 9 percent.”
— Cheryl Wellington, University of British Columbia researcher, speaking to Being Patient
Limits of the Evidence Presented
The supplied interview does not identify the studies behind the 7% to 9% estimate, specify how high LDL was defined, or give the time period and comparison group used to calculate the figure. It also does not quantify how much risk might change when LDL is lowered. Those details matter for interpreting the estimate and applying it to individuals.
The discussion describes possible mechanisms—including impaired amyloid-beta clearance and inflammation involving brain immune cells—but the source material does not establish that these mechanisms cause Alzheimer’s disease in people. It also does not describe a clinical trial showing that cholesterol-lowering medication prevents dementia, or say which treatment would be appropriate for any particular person.
Clinical Evidence and LDL Guidance
The Being Patient report is an interview rather than an announcement of new research, and it does not set out a forthcoming study or policy change. The next evidence readers would need includes clearly described studies tracking cholesterol over time, and trials that test whether lowering LDL changes dementia outcomes, not only cardiovascular measures.
For now, the interview’s practical message is to discuss LDL testing and management with a qualified health professional. Wellington’s comments support attention to midlife vascular health, but the report does not provide individualized treatment instructions or confirm that cholesterol treatment will prevent Alzheimer’s disease.
Key Questions
Does blood cholesterol pass directly into the brain?
Wellington said the blood-brain barrier limits direct exchange, and cholesterol in the bloodstream does not simply cross into the brain. She described blood-vessel and brain-tissue processes as separate but both relevant to neurological health.
What Alzheimer’s risk estimate did Wellington cite?
She cited an estimated 7% to 9% increase in risk of Alzheimer’s disease and related dementias associated with high LDL in midlife. The supplied interview does not provide the underlying study details, so the figure should be read as an attributed estimate rather than a personal prediction.
Does lowering LDL prevent Alzheimer’s disease?
The interview does not establish that lowering LDL prevents Alzheimer’s. Wellington said bringing LDL into range may reduce risk, but the source material does not report a prevention trial or quantify a treatment effect on dementia.
Should people change cholesterol treatment because of this report?
The report is not individualized medical advice. People with questions about LDL testing or treatment should discuss them with a qualified health professional, who can consider their overall health and medical history.
Source: beingpatient.com
